Cilnidipine: A Comprehensive Review of Pharmacological Properties, Novel Formulation Approaches, and Clinical Implications in Hypertension

Cilnidipine, a fourth-generation dihydropyridine calcium channel blocker, represents a significant advancement in hypertension management due to its unique dual L-type and N-type calcium channel blocking activity. Unlike conventional calcium channel blockers, cilnidipine provides antihypertensive effects without reflex tachycardia and offers additional renoprotective and neuroprotective benefits. However, its therapeutic potential is severely constrained by poor oral bioavailability (approximately 13%), arising from low aqueous solubility (BCS Class II) and extensive first-pass metabolism, coupled with a short half-life (~20 minutes). These pharmacokinetic limitations necessitate frequent dosing, compromising patient compliance and therapeutic efficacy. Gastroretentive floating tablet technology has emerged as a promising strategy to address these challenges by prolonging gastric residence time, enabling sustained drug release, and enhancing bioavailability. This comprehensive review systematically examines the formulation strategies, polymer selection, evaluation parameters, and drug release mechanisms of cilnidipine-loaded floating tablets. The role of hydrophilic polymers including HPMC, gellan gum, and polyethylene oxide in achieving optimal floating properties and extended-release profiles is critically analyzed. Characterization techniques, buoyancy performance, and in vitro-in vivo correlations from human volunteer studies are discussed. The review synthesizes current evidence demonstrating that optimized floating tablet formulations can sustain cilnidipine release for up to 12 hours, maintain buoyancy for over 6 hours, and significantly improve relative bioavailability compared to conventional formulations. Regulatory considerations, stability challenges, and future perspectives, including combination with solubility enhancement strategies, are also addressed. This comprehensive analysis establishes floating tablet technology as a viable and effective approach for optimizing cilnidipine therapy in the long-term management of hypertension and associated cardiovascular conditions.